Cizumab: A DGCI-Approved Bevacizumab Biosimilar for Cancer Treatment
Cizumab is a DGCI-approved Bevacizumab biosimilar injection designed to target various cancers, including colorectal, rectal, ovarian, kidney, cervical, lung, and brain tumors. As a biosimilar of Bevacizumab, Cizumab works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for forming new blood vessels that supply nutrients to tumors. By blocking VEGF, Cizumab helps slow tumor growth and can improve patient outcomes.
Uses and Dosage
Cizumab is commonly prescribed for:
-
Colon and rectum cancer – to reduce tumor progression in advanced stages.
-
Ovarian cancer – often combined with chemotherapy for better efficacy.
-
Cervical cancer – as part of targeted therapy for advanced or recurrent cases.
-
Kidney cancer – to inhibit angiogenesis and slow tumor growth.
-
Brain tumors – including glioblastoma, to limit tumor vascularization.
The typical dose of Bevacizumab (Cizumab) depends on the type of cancer and patient condition. For adults, it is often administered intravenously at doses like 400 mg per cycle, but treatment plans should always be personalized by an oncologist.
Side Effects
While Cizumab is effective, it may cause side effects, such as high blood pressure, fatigue, headache, bleeding, proteinuria (protein in urine), and in rare cases, gastrointestinal perforation. Patients must be monitored regularly during therapy to manage adverse effects effectively.
Conclusion
Cizumab represents a reliable Bevacizumab biosimilar injection option for patients seeking effective cancer treatment. With its targeted mechanism of action against VEGF, it helps manage tumor growth across multiple cancer types while offering a cost-effective alternative to the original biologic. Always consult an oncologist to determine the best treatment plan, dosage, and monitoring schedule.